BIA Separations Signs License Agreement with University of Zagreb

Bio-chromatography development and manufacturing company, BIA Separations, has signed a license agreement with the University of Zagreb to commercialize a novel elution method for virus and viral vector purification.

According to a Feb. 19, 2020 press release, the university will provide BIA Separations with access to proprietary technology to market to biopharma, biotech, and life science industries around the world. Additionally, under the terms of the agreement, research teams from both the university and the company will collaborate on the development of follow-on technologies to support the purification of viruses and viral vectors for research and clinical use.

“BIA Separations monolithic column technology is now well established and following this success we are focused on providing customers with a “one-stop-shop” for the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and any novel complex biopharma product,” said Aleš Štrancar, CEO of BIA Separations, in the press release. “To achieve fully integrated upstream and downstream processing with robust in-process control we are collaborating with other leaders in the industry to access the latest technologies and products. This agreement with the University Zagreb is one of a number currently in the pipeline and supports our ultimate goal.”

“The University of Zagreb is pleased to see solutions developed by our researchers contributing to improvements in medical biotechnology, and being brought closer to users through our work with innovation-oriented industry partners such as BIA Separations,” added Professor Miljenko Šimpraga, vice-rector for Innovation, Technology Transfer, and Communication at the University of Zagreb, in the press release. “As a research university, this is an important achievement which is fully aligned with our aim to create a positive impact on society.”

Source: BIA Separations